Samuel C. Blackman Sells 11,245 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 11,245 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $16.03, for a total value of $180,257.35. Following the transaction, the insider now directly owns 1,085,790 shares in the company, valued at $17,405,213.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Day One Biopharmaceuticals Trading Up 4.0 %

Shares of NASDAQ DAWN opened at $16.39 on Friday. The firm has a fifty day simple moving average of $14.34 and a two-hundred day simple moving average of $14.41. The firm has a market capitalization of $1.65 billion, a PE ratio of -15.91 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 12 month low of $10.90 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter last year, the business earned ($0.54) earnings per share. On average, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C grew its stake in Day One Biopharmaceuticals by 65.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after purchasing an additional 1,157,825 shares during the period. First Turn Management LLC bought a new position in shares of Day One Biopharmaceuticals in the 3rd quarter worth about $13,204,000. Estuary Capital Management LP lifted its position in Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock valued at $26,616,000 after acquiring an additional 728,240 shares during the period. Ally Bridge Group NY LLC bought a new stake in Day One Biopharmaceuticals during the second quarter worth about $7,387,000. Finally, Point72 Asset Management L.P. purchased a new stake in Day One Biopharmaceuticals in the second quarter worth about $6,480,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DAWN shares. Needham & Company LLC restated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the company from $11.00 to $24.00 in a report on Thursday, August 1st. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.